Activation of deep crypt secretory cells in colonic inflammation
Ended Project Grant Awarded Last action
- Award ID
- R01DK140323
- Recipient
-
Children's Hospital LOS Angeles UEI DVL1CMRMWRN9
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,136,643
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Place of performance
- Los Angeles, CA 90027, USA
Award details come from USAspending.gov.
Description
- Abstract
- An impaired epithelial lining is a key pathological element of numerous diseases of the colon; however, our understanding of how specific epithelial cell populations contribute to colonic health and disease is limited. Deep crypt secretory (DCS) cells are a poorly-understood epithelial cell lineage residing at the colonic crypt base. These cells express immuno-modulatory, host defense, and stem cell niche factors that are commonly dysregulated in inflammatory bowel disease (IBD) and other disorders. Thus, DCS cells represent an appealing potential therapeutic target for restoring tissue health in colonic inflammatory disease. A better understanding of the basic biology of DCS cells is essential for future therapies targeting the epithelium. In recent work we found that immune signaling regulates DCS cell population size, and our preliminary data suggest that key inflammation-responsive factors drive DCS cells to an "activated" state characterized by heightened levels of immuno-modulatory and host defense factors. This project is designed to elucidate a novel paradigm of DCS cell activation in the response to colitis and to determine the role(S) of these cells in colonic inflammation and recovery. In the proposed work, we will 1) test whether impaired DCS cell responses exacerbate colonic inflammation and/or limit tissue repair and regeneration, 2) define the function of activated DCS cells in the colon, and 3) determine the cellular mechanisms that regulate DCS cell population shifts and activation. This investigation into the functional roles and regulation of DCS cells in colitis could point to new therapeutic targets for IBD and the promotion of intestinal health.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $527,691 | |
| Amendment | $0 | |
| Amendment | $530,149 | |
| Original award | $551,112 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Children's Hospital LOS Angeles | $129,813 | |
| University Of Southern California | $40,470 |
Quick answers
Who received award R01DK140323?
R01DK140323 was awarded to Children's Hospital LOS Angeles by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on September 15, 2024.
How much is award R01DK140323 worth?
$2,136,643 has been obligated on R01DK140323.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award